Molecular cytogenetics of prostate cancer

Microscopy Research and Technique

Volumn 51, Issue 5, 2000, Pages 456-463

  Nupponen, Nina N ^b   Visakorpi, Tapio ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b NONE

Author keywords

AR; CGH; EIF3S3; FISH; Genetic alterations; Hormone refractory; Prostatic carcinoma

Indexed keywords

CYTOLOGY; DISEASES; FISH; FLUORESCENCE; FLUORESCENCE MICROSCOPY; GENES; UROLOGY;

AR; CHROMOSOMAL REGIONS; COMPARATIVE GENOMIC HYBRIDIZATIONS; EIF3S3; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ALTERATIONS; HORMONE-REFRACTORY; INDUSTRIALIZED COUNTRIES; PROSTATE CANCERS; PROSTATIC CARCINOMA;

REFRACTORY MATERIALS;

ARTICLE; CARCINOGENESIS; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MOLECULAR GENETICS; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR SUPPRESSOR GENE;

EID: 0034564129     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0029(20001201)51:5<456::AID-JEMT8>3.0.CO;2-H     Document Type: Article

References (99)

1. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson-Keller JJ, Lieber MM, Jenkins RB. 1994. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 54: 3998-4002.
2. Atkin NB, Baker MC. 1985. Chromosome 10 deletion in carcinoma of the prostate. N Engl J Med 31:312-315.
3. Bandyk MG, Zhao L, Troncoso P, Pisters LL, Palmer JL, von Eschenbach AC, Chung LW, Liang JC. 1994. Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer 9:19-27.
4. Baretton GB, Valina C, Vogt T, Schneiderbanger K, Diebold J, Lohrs U. 1994. Interphase cytogenetic analysis of prostatic carcinomas by use of nonisotopic in situ hybridization. Cancer Res 15:4472-4480.
5. Bentz M, Plesch A, Stilgenbauer S, Dohner H, Lichter P. 1998. Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer 21:172-175.
6. Bieche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R, Vidaud M. 1999. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 59:2759-2765.
7. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. 1993. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53:3369-3373.
8. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC. 1993. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53:3869-3873.
9. Brothman AR, Peehl DM, Patel AM, McNeal JE. 1990. Frequency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res 50:3795-3803.
10. Brothman AR, Patel AM, Peehl DM, Schellhammer PF. 1992. Analysis of prostatic tumor cultures using fluorescence in-situ hybridization (FISH). Cancer Genet Cytogenet 62:180-185.
11. Brothman AR, Watson MJ, Zhu XL, Williams BJ, Rohr LR. 1994. Evaluation of 20 archival prostate tumor specimens by fluorescence in situ hybridization (FISH). Cancer Genet Cytogenet 1:40-44.
12. Brothman AR, Maxwell TM, Cui J, Deubler DA, Zhu XL. 1999. Chromosomal clues to the development of prostate tumors. Prostate 38:303-312.
13. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP. 1999. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59:803-806.
14. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D. 1997. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57:4997-5000.
15. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH. 1994. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 11:153-162.
16. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. 1996. Genetic alterations in untreated metastases and androgen independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56:3091-3102.
17. Cher ML, Lewis PE, Banerjee M, Hurley PM, Sakr W, Grignon DJ, Powell IJ. 1998. A similar pattern of chromosomal alterations in prostate cancers from African-Americans and Caucasian Americans. Clin Cancer Res 4:1273-1278.
18. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R. 1993. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-400.
19. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ. 1996. Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 56:1142-1145.
20. Craft N, Shostak Y, Carey M, Sawyers CL. 1999. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285.
21. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. 1994. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478.
22. Deubler DA, Williams BJ, Zhu XL, Steele MR, Rohr LR, Jensen JC, Stephenson RA, Changus JE, Miller GJ, Becich MJ, Brothman AR. 1997. Allelic loss detected on chromosomes 8, 10, and 17 by fluorescence in situ hybridization using single-copy P1 probes on isolated nuclei from paraffin-embedded prostate tumors. Am J Pathol 150: 841-580.
23. Dong JT, Sipe TW, Hyytinen ER, Li CL, Heise C, McClintock DE, Grant CD, Chung LW, Frierson HF Jr. 1998. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 17:1979-1982.
24. du Manoir S, Speicher MR, Joos S, Schrock E, Popp S, Dohner H, Kovacs G, Robert-Nicoud M, Lichter P, Cremer T. 1993. Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet 90:590-610.
25. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV. 1995. Mutation of the MXI1 gene in prostate cancer. Nat Genet 9:249-255.
26. Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. 1998. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16:1743-1748.
27. Forozan F, Karhu R, Kononen J, Kallioniemi A, Kallioniemi OP. 1997. Genome screening by comparative genomic hybridization. Trends Genet 13:405-409.
28. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK. 1995. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 55:4800-4803.
29. Gray JW, Pinkel D. 1992. Molecular cytogenetics in human cancer diagnosis. Cancer 69:1536-1542.
30. Heiskanen MA, Bittner ML, Chen Y, Khan J, Adler KE, Trent JM, Meltzer PS. 2000. Detection of gene amplification by genomic hybridization to cDNA microarrays. Cancer Res 60:799-802.
31. Hopman AH, Wiegant J, Raap AK, Landegent JE, van der Ploeg M, van Duijn P. 1986. Bi-color detection of two target DNAs by nonradioactive in situ hybridization. Histochemistry 85:1-4.
32. Hyytinen ER, Frierson HF Jr, Boyd JC, Chung LW, Dong JT. 1999. Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer 25:108-114.
33. Isola J, DeVries S, Chu L, Ghazvini S, Waldman F. 1994. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 145:1301-1308.
34. Jenkins RB, Qian J, Lieber MM, Bostwick DG. 1997. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57:524-531.
35. Jenkins RB, Qian J, Lee HK, Huang H, Hirasawa K, Bostwick DG, Proffitt J, Wilber K, Lieber MM, Liu W, Smith DI. 1998. A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res 58:759-766.
36. Joos S, Bergerheim US, Pan Y, Matsuyama H, Bentz M, du Manoir S, Lichter P. 1995. Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Genes Chromosomes Cancer 14:267-276.
37. Kallioniemi OP, Visakorpi T. 1996. Genetic basis and clonal evolution of human prostate cancer. Adv Cancer Res 68:225-255.
38. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. 1992. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818-821.
39. Kallioniemi OP, Kallioniemi A, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. 1993. Comparative genomic hybridization: a rapid new method for detecting and mapping DNA amplification in tumors. Semin Cancer Biol 4:41-46.
40. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D. 1994. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10:231-243.
41. Kawamata N, Park D, Wilczynski S, Yokota J, Koeffler HP. 1996. Point mutations of the Mxil gene are rare in prostate cancers. Prostate 29:191-193.
42. Kirchoff M, Gerdes T, Maahr J, Rose H, Bentz M, Dohner H, Lundsteen C. 1999. Deletions below 10 megabasepairs are detected in comparative genomic hybridization by standard reference intervals. Genes Chromosomes Cancer 25:410-413.
43. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP. 1997. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314-319.
44. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. 1998. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152:1-9.
45. Konig JJ, Teubel W, van Dongen JW, Hagemeijer A, Romijn JC, Schroder FH. 1993. Tissue culture loss of aneuploid cells from carcinomas of the prostate. Genes Chromosomes Cancer 8:22-27.
46. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. 1998. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847.
47. Kuukasjärvi T, Tanner M, Pennanen S, Karhu R, Visakorpi T, Isola J. 1997. Optimizing DOP-PCR for universal amplification of small DNA samples in comparative genomic hybridization. Genes Chromosomes Cancer 18:94-101.
48. Li C, Larsson C, Futreal A, Lancaster J, Phelan C, Aspenblad U, Sundelin B, Liu Y, Ekman P, Auer G, Bergerheim US. 1998. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 16:481-487.
49. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947.
50. Lundgren R, Kristoffersson U, Heim S, Mandahl N, Mitelman F. 1988. Multiple structural chromosome rearrangements, including del(7q) and del(10q), in an adenocarcinoma of the prostate. Cancer Genet Cytogenet 35:103-108.
51. Lundgren R, Mandahl N, Heim S, Limon J, Henrikson H, Mitelman F. 1992. Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes Chromosomes Cancer 4:16-24.
52. MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R. 1994. Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosomes Cancer 10: 151-159.
53. Macoska JA, Trybus TM, Sakr WA, Wolf MC, Benson PD, Powell IJ, Pontes JE. 1994. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res 54:3824-3830.
54. Matsuyama H, Pan Y, Skoog L, Tribukait B, Naito K, Ekman P, Lichter P, Bergerheim US. 1994. Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization. Oncogene 9:3071-3076.
55. Mitelman F, Mertens F, Johansson B. 1997. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 15 Special No: 417-474.
56. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. 1993. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1669.
57. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. 1999. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 161:304-308.
58. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. 1998. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 153:141-148.
59. Nupponen NN, Porkka K, Kakkola L, Borg Å, Tanner M, Isola J, Visakorpi T. 1999. Amplification and overexpression of p40 subunit of eukaryotic translation initation factor 3 in breast and prostate cancer. Am J Pathol 154:1777-1783.
60. Nupponen NN, Isola J, Visakorpi T. 2000. Mapping the amplification of EIF3S3 in breast and prostate cancer. Genes Chrom Cancer 28:203-210.
61. Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi O-P, Tammela T. 1997. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with nonsteroidal potent antiandrogen "Casodex" (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol 31:216-219.
62. Palmberg C, Koivisto L, Tammela TLJ, Kallioniemi OP, Visakorpi T. 2000. Androgen receptor gene amplification at the time of primary progression predicts response to combined androgen blockade as a second-line therapy in advanced prostate cancer. J Urology, in press.
63. Pan Y, Kytölä S, Farnebo F, Wang N, Onn Lui W, Nupponen N, Isola J, Visakorpi T, Bergerheim USR, Larsson C. 1999. Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. Cytogenet Cell Genet 87:225-232.
64. Persson K, Pandis N, Mertens F, Borg Å, Baldetorp B, Killander D, Isola J. 1999. Chromosomal aberrations in breast cancer: a comparison between cytogenetics and comparative genomic hybridization. Genes Chromosomes Cancer 25:115-122.
65. Pesche S, Latil A, Muzeau F, Cussenot O, Fournier G, Longy M, Eng C, Lidereau R. 1998. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 16:2879-2883.
66. Pinkel D, Straume T, Gray JW. 1986. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci 83:2934-2938.
67. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG. 1998. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20:207-211.
68. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO. 1999. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23:41-46.
69. Porkka K, Visakorpi T. 2000. Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library array. J Pathol in press.
70. Prochownik EV, Eagle Grove L, Deubler D, Zhu XL, Stephenson RA, Rohr LR, Yin X, Brothman AR. 1998. Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Genes Chromosomes Cancer 22:295-304.
71. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, Jenkins RB. 1995. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55:5408-5414.
72. Qian J, Jenkins RB, Bostwick DG. 1999. Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Eur Urol 35:479-483.
73. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. 1998. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci 95:1735-1740.
74. Reiter RE, Sato I, Thomas G, Qian J, Gu Z, Watabe T, Loda M, Jenkins RB. 2000. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 27:95-103.
75. Ried T, Liyanage M, du Manoir S, Heselmeyer K, Auer G, Macville M, Schrock E. 1997. Tumor cytogenetics revisited: comparative genomic hybridization and spectral karyotyping. J Mol Med 75:801-814.
76. Sandberg AA. 1992. Chromosomal abnormalities and related events in prostate cancer. Hum Pathol 23:368-380.
77. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, Jenkins RB. 1999. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 91:1574-1580.
78. Sattler HP, Rohde V, Bonkhoff H, Zwergel T, Wullich B. 1999. Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate 39:79-86.
79. Schreiber-Agus N, Meng Y, HoangT, Hou H Jr, Chen K, Greenberg R, Cordon-Cardo C, Lee HW, DePinho RA. 1998. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 393:483-487.
80. Schröck E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Y, Ried T. 1996. Multicolor spectral karyotyping of human chromosomes. Science 273:494-497.
81. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Dohner H, Cremer T, Lichter P. 1997. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 20:399-407.
82. Speicher MR, du Manoir S, Schrock E, Holtgreve-Grez H, Schoell B, Lengauer C, Cremer T, Ried T. 1993. Molecular cytogenetic analysis of formalin-fixed, paraffin-embedded solid tumors by comparative genomic hybridization after universal DNA-amplification. Hum Mol Genet 2:1907-1914.
83. Speicher MR, Gwyn Ballard S, Ward DC. 1996. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet 12: 368-375.
84. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362.
85. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS. 1998. Interfocal heterogeneity of PTEN/ MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58:204-209.
86. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB. 1994. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 54:3574-3579.
87. Takahashi S, Alcaraz A, Brown JA, Borell TJ, Herath JF, Bergstralh EJ, Lieber MM, Jenkins RB. 1996. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma. Clin Cancer Res 2:137-145.
88. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. 1999. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59: 2511-2515.
89. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. 1998. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 21:177-184.
90. Trapman J, Sleddens HF, van der Weiden MM, Dinjens WN, Konig JJ, Schroder FH, Faber PW, Bosman FT. 1994. Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 54:6061-6064.
91. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA. 1994. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54:3929-3933.
92. Van den Berg C, Guan X-Y, Von Hoff D, Jenkins R, Bittner M, Griffin C, Kallioniemi O, Visakorpi T, McGill J, Herath J, Epstein J, Saroscy M, Metzer P, Trent J. 1995. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: Potential prognostic implications. Clin Cancer Res 1:11-18.
93. Visakorpi T, Kallioniemi AH, Syvänen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. 1995a. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55:342-347.
94. Visakorpi T, Hyytinen E, Kallioniemi A, Isola J, Kallioniemi O-P. 1994. Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol 145:1-7.
95. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. 1995b. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406.
96. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM. 1996. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 56:2411-2416.
97. Wallen MJ, Linja M, Kaartinen K, Schleutker J, Visakorpi T. 1999. Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 1894:559-563.
98. Wang SI, Parsons R, Ittmann M. 1998. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 4:811-815.
99. Wiltshire RN, Duray P, Bittner ML, Visakorpi T, Meltzer PS, Tuthill RJ, Liotta LA, Trent JM. 1995. Direct visualization of the clonal progression of primary cutaneous melanoma: application of tissue microdissection and comparative genomic hybridization. Cancer Res 55:3954-3957.